Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

He Yan

Showing results (511-520 of 518) with videos related to

Pageof 52
Sort By:
You have reached the last page of results.This site can display upto 518 results.
Nature Communications|July 16, 2025
Revealing electron transport connectivity as an important factor influencing stability of organic solar cellsHaixia Hu, Rui Zhang, Dongcheng Jiang, et al.
Scientific Reports|June 2, 2026
Progression-free survival as a potential surrogate endpoint for overall survival after conversion therapy for unresectable hepatocellular carcinoma (GUIDANCE008)Jin-Wei Wu, Da-Long Yang, Shu-Chang Chen, et al.
Liver Cancer|June 11, 2025
Survival Benefit of Hepatectomy after Complete or Partial Response to Conversion Therapy in Unresectable Hepatocellular Carcinoma (GUIDANCE003): A Multicenter StudyDa-Long Yang, Ning Peng, Jun-Liang Nong, et al.
Hepatology (Baltimore, Md.)|February 5, 2025
Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stagesDa-Long Yang, Lin Ye, Fan-Jian Zeng, et al.
Hepatology (Baltimore, Md.)|June 25, 2025
Erratum: Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stagesDa-Long Yang, Lin Ye, Fan-Jian Zeng, et al.
Liver Cancer|January 19, 2026
Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE006)Liang Ma, Da-Long Yang, Teng-Meng Zhong, et al.
JHEP Reports : Innovation in Hepatology|October 27, 2025
Prognostic value of radiological and pathological complete response following immune-based conversion therapy in patients with unresectable hepatocellular carcinoma (GUIDANCE004)Da-Long Yang, Yi-He Yan, Yong-Cheng Lai, et al.
Communications Medicine|March 13, 2026
Neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors improves survival from resectable hepatocellular carcinoma in a multicenter, retrospective study (GUIDANCE002)Da-Long Yang, Chuang Qin, Ning Peng, et al.
Pageof 52

Showing results (511-520 of 518) with videos related to

Sort By:
Pageof 52
You have reached the last page of results.This site can display upto 518 results.
Nature Communications|July 16, 2025
Revealing electron transport connectivity as an important factor influencing stability of organic solar cellsHaixia Hu, Rui Zhang, Dongcheng Jiang, et al.
Scientific Reports|June 2, 2026
Progression-free survival as a potential surrogate endpoint for overall survival after conversion therapy for unresectable hepatocellular carcinoma (GUIDANCE008)Jin-Wei Wu, Da-Long Yang, Shu-Chang Chen, et al.
Liver Cancer|June 11, 2025
Survival Benefit of Hepatectomy after Complete or Partial Response to Conversion Therapy in Unresectable Hepatocellular Carcinoma (GUIDANCE003): A Multicenter StudyDa-Long Yang, Ning Peng, Jun-Liang Nong, et al.
Hepatology (Baltimore, Md.)|February 5, 2025
Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stagesDa-Long Yang, Lin Ye, Fan-Jian Zeng, et al.
Hepatology (Baltimore, Md.)|June 25, 2025
Erratum: Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stagesDa-Long Yang, Lin Ye, Fan-Jian Zeng, et al.
Liver Cancer|January 19, 2026
Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE006)Liang Ma, Da-Long Yang, Teng-Meng Zhong, et al.
JHEP Reports : Innovation in Hepatology|October 27, 2025
Prognostic value of radiological and pathological complete response following immune-based conversion therapy in patients with unresectable hepatocellular carcinoma (GUIDANCE004)Da-Long Yang, Yi-He Yan, Yong-Cheng Lai, et al.
Communications Medicine|March 13, 2026
Neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors improves survival from resectable hepatocellular carcinoma in a multicenter, retrospective study (GUIDANCE002)Da-Long Yang, Chuang Qin, Ning Peng, et al.
Pageof 52